Perfromance Wealth Partners LLC Sells 144 Shares of Eli Lilly and Company (NYSE:LLY)

Perfromance Wealth Partners LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 70,054 shares of the company’s stock after selling 144 shares during the quarter. Eli Lilly and Company makes up approximately 1.7% of Perfromance Wealth Partners LLC’s portfolio, making the stock its 11th largest position. Perfromance Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $54,082,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in LLY. Octavia Wealth Advisors LLC grew its holdings in shares of Eli Lilly and Company by 25.0% during the 4th quarter. Octavia Wealth Advisors LLC now owns 735 shares of the company’s stock worth $568,000 after purchasing an additional 147 shares in the last quarter. Commons Capital LLC grew its holdings in shares of Eli Lilly and Company by 14.0% during the 4th quarter. Commons Capital LLC now owns 408 shares of the company’s stock worth $315,000 after purchasing an additional 50 shares in the last quarter. Fort Washington Investment Advisors Inc. OH grew its holdings in shares of Eli Lilly and Company by 2.0% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 2,226 shares of the company’s stock worth $1,718,000 after purchasing an additional 44 shares in the last quarter. Enclave Advisors LLC grew its holdings in shares of Eli Lilly and Company by 7.9% during the 4th quarter. Enclave Advisors LLC now owns 410 shares of the company’s stock worth $317,000 after purchasing an additional 30 shares in the last quarter. Finally, Mogy Joel R Investment Counsel Inc. boosted its stake in Eli Lilly and Company by 1.7% in the fourth quarter. Mogy Joel R Investment Counsel Inc. now owns 35,008 shares of the company’s stock valued at $27,026,000 after buying an additional 593 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 1.6 %

Shares of LLY stock opened at $766.00 on Friday. The company has a market cap of $727.18 billion, a P/E ratio of 82.81, a PEG ratio of 1.56 and a beta of 0.41. The stock has a 50 day simple moving average of $776.31 and a two-hundred day simple moving average of $850.93. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. Eli Lilly and Company has a fifty-two week low of $624.68 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. During the same period last year, the business posted $0.10 EPS. The company’s revenue was up 20.4% on a year-over-year basis. Research analysts forecast that Eli Lilly and Company will post 12.98 earnings per share for the current year.

Eli Lilly and Company declared that its Board of Directors has initiated a stock buyback plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a dividend of $1.50 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.78%. Eli Lilly and Company’s payout ratio is presently 56.22%.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.13% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on LLY shares. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Citigroup raised their price objective on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research note on Friday, October 25th. Bank of America reaffirmed a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Finally, Sanford C. Bernstein initiated coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price target on the stock. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,002.22.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.